Ocugen (OCGN) Other Non-Current Liabilities (2014 - 2026)
Ocugen (OCGN) reported Other Non-Current Liabilities of $3.0 million for Q1 2026, up 415.01% on a YoY basis from $573000.0 in Q1 2025, and up 84.09% quarter-over-quarter from $1.6 million in Q4 2025.
Ocugen (OCGN) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Ocugen has reported Other Non-Current Liabilities for 12 years, with the latest figure at $3.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 415.01% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (up 415.01% YoY), and the FY2025 full-year result was $1.6 million, up 184.22% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $3.0 million, up from $1.6 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $3.0 million in Q1 2026, with the low at $244000.0 in Q4 2022.
- Historically, Other Non-Current Liabilities has averaged $823857.1 across 5 years, with a median of $549500.0 in 2024.
- Annual changes were most pronounced in 2025 — Other Non-Current Liabilities climbed 6.9% — and 2026, when it soared 415.01%.
- Ocugen's Other Non-Current Liabilities stood at $244000.0 in 2022, then surged by 115.98% to $527000.0 in 2023, then grew by 7.02% to $564000.0 in 2024, then surged by 184.22% to $1.6 million in 2025, then jumped by 84.09% to $3.0 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $3.0 million (Q1 2026), $1.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.95 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | 583,000.00 |
| Mar 31, 2025 | 573,000.00 |
| Dec 31, 2024 | 564,000.00 |
| Sep 30, 2024 | 554,000.00 |
| Jun 30, 2024 | 545,000.00 |
| Mar 31, 2024 | 536,000.00 |
| Dec 31, 2023 | 527,000.00 |
| Sep 30, 2023 | 497,000.00 |
| Jun 30, 2023 | 455,000.00 |
| Mar 31, 2023 | 309,000.00 |
| Dec 31, 2022 | 244,000.00 |
| Mar 31, 2020 | 3,940.00 |
| Dec 31, 2019 | 9,755.00 |
| Jun 30, 2019 | 64,347.00 |
| Mar 31, 2019 | 10,000.00 |
| Dec 31, 2018 | 37,459.00 |
| Sep 30, 2018 | 1.09 Mn |